Last week, Canadian pot producer Canopy Growth agreed to buy U.S. seller Acreage Holdings once cannabis becomes legal under U.S. federal law. More than 30 states have legalized marijuana under their laws, but it’s still federally prohibited.

So what does the Acreage deal mean for Canopy Growth’s 38% owner—the beer and wine seller Constellation Brands (ticker: STZ)?

Wells Fargo analyst Bonnie Herzog couldn’t be more upbeat. In a recent note, she pointed out that Canopy’s Acreage deal coincided with some tweaks in an agreement that lets Constellation lift its Canopy stake to 50%. Those adjustments fix the price and give Constellation more time to exercise that option.

And that will ease demands on Constellation’s cash, Herzog said. In earlier research, she has raised concern about the drag of Canopy’s losses on Constellation. Her rating on Constellation stock remains an Outperform, with a $235 price target.

In Monday morning trading, Constellation stock was up 3% to $205. Canopy’s NYSE-listed stock (CGC) rose 5% to $47, while Acreage (ACRGF.OTC), listed on the OTC Markets Group, was off 2% to $22.

Constellation’s involvement in Canopy and cannabis, writes the Wells analyst, sets up the company “to take a leading position in the global alcohol/cannabis industry over the next decade plus.”

When the alcoholic beverage seller paid $4 billion last year for its 38% of Canopy, the deal gave Constellation warrants to buy stock that could lift its ownership above 50%. Constellation would have to exercise the warrants within three years and pay the price of Canopy stock at the time it did so.

Last week’s change gives Constellation between five and eight years to exercise its warrants and fixes the price for three-fourths of the tranche at 76.68 Canadian dollars. On the Toronto exchange Monday morning, Canopy stock was going for C$62.55 (or US$46.91).

Last Thursday’s deal between Canopy and Acreage says that the Canadian firm will buy the American pot chain for US$3.4 billion, when Congress and the president make the stuff federally legal. A bill called the STATES Act—introduced last year but not voted on—would have federally decriminalized pot wherever marijuana is legal under state law. The bill was reintroduced last week.

Acreage’s acquisition deal jolted the stocks of other U.S. pot chains. Federal illegality has kept their shares off major exchanges, so they are listed on the junior Canadian Securities Exchange and the U.S.’s OTC Markets Group.

Since last week’s news, Curaleaf Holdings (CURLF.OTC), Harvest Health & Recreation (HRVSF.OTC), Cresco Labs (CRLBF.OTC) and Green Thumb Industries (GTBIF.OTC) have all risen by about 10%. Acreage, Trulieve Cannabis (TCNNF.OTC) and iAnthus Capital Holdings (ITHUF.OTC) are up about 5%, while MedMen Enterprises Holdings (MMNFF.OTC) is flat.

A February story in Barron’ssurveyed the many hurdles in the path of these U.S. cannabis stocks. Shares in MedMen and iAnthus have remained flat since then, while Acreage stock has matched the Nasdaq Composite’s gains. Green Thumb and Trulieve shares are some 15% higher, while Harvest stock is up nearly 20%. Curaleaf has soared more than 40%.